These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 10894878)

  • 21. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
    Hidalgo M; Villalona-Calero MA; Eckhardt SG; Drengler RL; Rodriguez G; Hammond LA; Diab SG; Weiss G; Garner AM; Campbell E; Davidson K; Louie A; O'Neil JD; von Borstel R; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 2000 Jan; 18(1):167-77. PubMed ID: 10623707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
    Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
    Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
    Fukushima M; Shimamoto Y; Kato T; Uchida J; Yonekura R; Ohshimo H; Shirasaka T
    Anticancer Drugs; 1998 Oct; 9(9):817-23. PubMed ID: 9840729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. S-1 in gastric cancer: a comprehensive review.
    Maehara Y
    Gastric Cancer; 2003; 6 Suppl 1():2-8. PubMed ID: 12775012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
    Kochi M; Fujii M; Kanamori N; Kaiga T; Aizaki K; Takahashi T; Takayama T
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):693-701. PubMed ID: 17690883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study.
    Ueda Y; Yamagishi H; Yamashita T; Itoh N; Itoi H; Shirasaka T; Ajani JA
    Jpn J Clin Oncol; 2004 May; 34(5):282-6. PubMed ID: 15231865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Phase I study of S-1. S-1 Study Group].
    Taguchi T; Inuyama Y; Kanamaru R; Hasegawa K; Akazawa S; Niitani H; Furue H; Kurihara M; Ota K; Suga S; Ariyoshi Y; Takai S; Shimoyama T; Toge T; Takashima S; Sugimachi K; Hara Y; Fujita H; Kimura K; Saito T; Tsukagoshi S; Nakao I
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2253-64. PubMed ID: 9422070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
    Yamamoto K; Imamura H; Furukawa H; Kishimoto T; Tanaka J; Oshiro R; Tatsuta M; Masutani S; Fukunaga M; Nakayama T; Takemoto H; Kondo M; Kamigaki S; Kawasaki T
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1748-51. PubMed ID: 16315929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternate-day oral therapy with TS-1 for advanced gastric cancer.
    Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T
    Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.
    Comets E; Ikeda K; Hoff P; Fumoleau P; Wanders J; Tanigawara Y
    J Pharmacokinet Pharmacodyn; 2003 Aug; 30(4):257-83. PubMed ID: 14650374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
    Booka E; Imamura CK; Takeuchi H; Hamamoto Y; Gomi D; Mizukami T; Ichiyama T; Tateishi K; Takahashi T; Kawakubo H; Soejima K; Boku N; Tanigawara Y; Kitagawa Y
    Gastric Cancer; 2016 Jul; 19(3):876-86. PubMed ID: 26304171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
    Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of initial full and subsequent reduced doses of S-1 in patients with locally advanced head and neck cancer-effect of renal insufficiency.
    Yamazaki T; Tahara M; Enokida T; Wakasugi T; Arahira S; Zenda S; Motegi A; Akimoto T; Yoshisue K
    Jpn J Clin Oncol; 2017 May; 47(5):407-412. PubMed ID: 28159957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
    Ohtsu A; Baba H; Sakata Y; Mitachi Y; Horikoshi N; Sugimachi K; Taguchi T
    Br J Cancer; 2000 Jul; 83(2):141-5. PubMed ID: 10901361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas.
    Fujita K; Ichikawa W; Yamamoto W; Endo H; Nagashima F; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Sasaki Y
    Ann Oncol; 2009 May; 20(5):946-9. PubMed ID: 19150953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling.
    Kim TH; Shin S; Shin JC; Bulitta JB; Weon KY; Yoo SD; Park GY; Jeong SW; Kwon DR; Min BS; Woo MH; Shin BS
    Molecules; 2017 Sep; 22(9):. PubMed ID: 28880240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
    Blum M; Suzuki A; Ajani JA
    Future Oncol; 2011 Jun; 7(6):715-26. PubMed ID: 21675835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.
    Sakata Y; Ohtsu A; Horikoshi N; Sugimachi K; Mitachi Y; Taguchi T
    Eur J Cancer; 1998 Oct; 34(11):1715-20. PubMed ID: 9893658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
    Liu HY; Ding L; Yu Y; Chu Y; Zhu H
    Yao Xue Xue Bao; 2012 Oct; 47(10):1363-9. PubMed ID: 23289150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.